Skip to Content
Kenneth  Wyman

Kenneth Wyman, M.D.

Assistant Professor of Medicine


Dr. Kenneth Wyman is a medical oncologist who specializes in solid tumor oncology and primarily sees patients at the Veteran's Administration Hospital in Nashville.  His interests include melanoma and gastrointestinal oncology.  He is involved in a variety of ongoing clinical research activities at both The Vanderbilt Clinic and the Veteran's Administration Hospital.

  • B.S. - Murray State University, 1986
  • M.D. - University of Louisville, 1993
  • Internship - Vanderbilt University Medical Center, 1994
  • Residency - Vanderbilt University Medical Center, 1996
  • Fellowship - Vanderbilt University Medical Center, 1998
  • Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006 May 5/1/2006; 106(9): 2005-11. PMID: 16565971, DOI: 10.1002/cncr.21834, ISSN: 0008-543X.
    Available from:
  • Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother Oncol. 2005 Jul; 76(1): 54-8. PMID: 15921772, PII: S0167-8140(05)00169-6, DOI: 10.1016/j.radonc.2005.04.005, ISSN: 0167-8140.
    Available from:
  • Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, Shyr Y, Caillouette C, Chakravarthy B. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005 Apr 4/1/2005; 61(5): 1364-70. PMID: 15817338, PII: S0360-3016(04)02471-X, DOI: 10.1016/j.ijrobp.2004.08.050, ISSN: 0360-3016.
    Available from: